Advertisement
- Corrigendum (June 2014)
Sympathetic activity–associated periodic repolarization dynamics predict mortality following myocardial infarction
Konstantinos D. Rizas,1 Tuomo Nieminen,2 Petra Barthel,3 Christine S. Zürn,1 Mika Kähönen,4 Jari Viik,5 Terho Lehtimäki,6 Kjell Nikus,7 Christian Eick,1 Tim O. Greiner,8 Hans P. Wendel,8 Peter Seizer,1 Jürgen Schreieck,1 Meinrad Gawaz,1 Georg Schmidt,3 and Axel Bauer1
1Medizinische Klinik III, Abteilung für Kardiologie und Herz-Kreislauferkrankungen, Eberhard Karls University, Tübingen, Germany. 2Division of Cardiology, Helsinki University Central Hospital, Helsinki, Finland. 31. Medizinische Klinik, Technische Universität München, Munich, Germany. 4Department of Clinical Physiology and 5Department of Biomedical Engineering, Tampere University of Technology, Tampere, Finland. 6Department of Clinical Chemistry, Fimlab Laboratories, School of Medicine at University of Tampere, Tampere, Finland. 7Heart Centre, Department of Cardiology, Tampere University Hospital, Tampere, Finland. 8Department of Thoracic, Cardiac and Vascular Surgery, Eberhard Karls University, Tübingen, Germany.
Address correspondence to: Axel Bauer, Medizinische Klinik III, Abteilung für Kardiologie und Herz-Kreislauferkrankungen, Eberhard-Karls-Universität Tübingen, Otfried-Müller-Str. 10, 72076 Tübingen, Germany. Phone: 49.7071.29.82922; Fax: 49.7071.29.4550; E-mail: bauer@thebiosignals.org.
Find articles by Rizas, K. in: PubMed | Google Scholar
1Medizinische Klinik III, Abteilung für Kardiologie und Herz-Kreislauferkrankungen, Eberhard Karls University, Tübingen, Germany. 2Division of Cardiology, Helsinki University Central Hospital, Helsinki, Finland. 31. Medizinische Klinik, Technische Universität München, Munich, Germany. 4Department of Clinical Physiology and 5Department of Biomedical Engineering, Tampere University of Technology, Tampere, Finland. 6Department of Clinical Chemistry, Fimlab Laboratories, School of Medicine at University of Tampere, Tampere, Finland. 7Heart Centre, Department of Cardiology, Tampere University Hospital, Tampere, Finland. 8Department of Thoracic, Cardiac and Vascular Surgery, Eberhard Karls University, Tübingen, Germany.
Address correspondence to: Axel Bauer, Medizinische Klinik III, Abteilung für Kardiologie und Herz-Kreislauferkrankungen, Eberhard-Karls-Universität Tübingen, Otfried-Müller-Str. 10, 72076 Tübingen, Germany. Phone: 49.7071.29.82922; Fax: 49.7071.29.4550; E-mail: bauer@thebiosignals.org.
Find articles by Nieminen, T. in: PubMed | Google Scholar
1Medizinische Klinik III, Abteilung für Kardiologie und Herz-Kreislauferkrankungen, Eberhard Karls University, Tübingen, Germany. 2Division of Cardiology, Helsinki University Central Hospital, Helsinki, Finland. 31. Medizinische Klinik, Technische Universität München, Munich, Germany. 4Department of Clinical Physiology and 5Department of Biomedical Engineering, Tampere University of Technology, Tampere, Finland. 6Department of Clinical Chemistry, Fimlab Laboratories, School of Medicine at University of Tampere, Tampere, Finland. 7Heart Centre, Department of Cardiology, Tampere University Hospital, Tampere, Finland. 8Department of Thoracic, Cardiac and Vascular Surgery, Eberhard Karls University, Tübingen, Germany.
Address correspondence to: Axel Bauer, Medizinische Klinik III, Abteilung für Kardiologie und Herz-Kreislauferkrankungen, Eberhard-Karls-Universität Tübingen, Otfried-Müller-Str. 10, 72076 Tübingen, Germany. Phone: 49.7071.29.82922; Fax: 49.7071.29.4550; E-mail: bauer@thebiosignals.org.
Find articles by Barthel, P. in: PubMed | Google Scholar
1Medizinische Klinik III, Abteilung für Kardiologie und Herz-Kreislauferkrankungen, Eberhard Karls University, Tübingen, Germany. 2Division of Cardiology, Helsinki University Central Hospital, Helsinki, Finland. 31. Medizinische Klinik, Technische Universität München, Munich, Germany. 4Department of Clinical Physiology and 5Department of Biomedical Engineering, Tampere University of Technology, Tampere, Finland. 6Department of Clinical Chemistry, Fimlab Laboratories, School of Medicine at University of Tampere, Tampere, Finland. 7Heart Centre, Department of Cardiology, Tampere University Hospital, Tampere, Finland. 8Department of Thoracic, Cardiac and Vascular Surgery, Eberhard Karls University, Tübingen, Germany.
Address correspondence to: Axel Bauer, Medizinische Klinik III, Abteilung für Kardiologie und Herz-Kreislauferkrankungen, Eberhard-Karls-Universität Tübingen, Otfried-Müller-Str. 10, 72076 Tübingen, Germany. Phone: 49.7071.29.82922; Fax: 49.7071.29.4550; E-mail: bauer@thebiosignals.org.
Find articles by Zürn, C. in: PubMed | Google Scholar
1Medizinische Klinik III, Abteilung für Kardiologie und Herz-Kreislauferkrankungen, Eberhard Karls University, Tübingen, Germany. 2Division of Cardiology, Helsinki University Central Hospital, Helsinki, Finland. 31. Medizinische Klinik, Technische Universität München, Munich, Germany. 4Department of Clinical Physiology and 5Department of Biomedical Engineering, Tampere University of Technology, Tampere, Finland. 6Department of Clinical Chemistry, Fimlab Laboratories, School of Medicine at University of Tampere, Tampere, Finland. 7Heart Centre, Department of Cardiology, Tampere University Hospital, Tampere, Finland. 8Department of Thoracic, Cardiac and Vascular Surgery, Eberhard Karls University, Tübingen, Germany.
Address correspondence to: Axel Bauer, Medizinische Klinik III, Abteilung für Kardiologie und Herz-Kreislauferkrankungen, Eberhard-Karls-Universität Tübingen, Otfried-Müller-Str. 10, 72076 Tübingen, Germany. Phone: 49.7071.29.82922; Fax: 49.7071.29.4550; E-mail: bauer@thebiosignals.org.
Find articles by Kähönen, M. in: PubMed | Google Scholar
1Medizinische Klinik III, Abteilung für Kardiologie und Herz-Kreislauferkrankungen, Eberhard Karls University, Tübingen, Germany. 2Division of Cardiology, Helsinki University Central Hospital, Helsinki, Finland. 31. Medizinische Klinik, Technische Universität München, Munich, Germany. 4Department of Clinical Physiology and 5Department of Biomedical Engineering, Tampere University of Technology, Tampere, Finland. 6Department of Clinical Chemistry, Fimlab Laboratories, School of Medicine at University of Tampere, Tampere, Finland. 7Heart Centre, Department of Cardiology, Tampere University Hospital, Tampere, Finland. 8Department of Thoracic, Cardiac and Vascular Surgery, Eberhard Karls University, Tübingen, Germany.
Address correspondence to: Axel Bauer, Medizinische Klinik III, Abteilung für Kardiologie und Herz-Kreislauferkrankungen, Eberhard-Karls-Universität Tübingen, Otfried-Müller-Str. 10, 72076 Tübingen, Germany. Phone: 49.7071.29.82922; Fax: 49.7071.29.4550; E-mail: bauer@thebiosignals.org.
Find articles by Viik, J. in: PubMed | Google Scholar
1Medizinische Klinik III, Abteilung für Kardiologie und Herz-Kreislauferkrankungen, Eberhard Karls University, Tübingen, Germany. 2Division of Cardiology, Helsinki University Central Hospital, Helsinki, Finland. 31. Medizinische Klinik, Technische Universität München, Munich, Germany. 4Department of Clinical Physiology and 5Department of Biomedical Engineering, Tampere University of Technology, Tampere, Finland. 6Department of Clinical Chemistry, Fimlab Laboratories, School of Medicine at University of Tampere, Tampere, Finland. 7Heart Centre, Department of Cardiology, Tampere University Hospital, Tampere, Finland. 8Department of Thoracic, Cardiac and Vascular Surgery, Eberhard Karls University, Tübingen, Germany.
Address correspondence to: Axel Bauer, Medizinische Klinik III, Abteilung für Kardiologie und Herz-Kreislauferkrankungen, Eberhard-Karls-Universität Tübingen, Otfried-Müller-Str. 10, 72076 Tübingen, Germany. Phone: 49.7071.29.82922; Fax: 49.7071.29.4550; E-mail: bauer@thebiosignals.org.
Find articles by Lehtimäki, T. in: PubMed | Google Scholar
1Medizinische Klinik III, Abteilung für Kardiologie und Herz-Kreislauferkrankungen, Eberhard Karls University, Tübingen, Germany. 2Division of Cardiology, Helsinki University Central Hospital, Helsinki, Finland. 31. Medizinische Klinik, Technische Universität München, Munich, Germany. 4Department of Clinical Physiology and 5Department of Biomedical Engineering, Tampere University of Technology, Tampere, Finland. 6Department of Clinical Chemistry, Fimlab Laboratories, School of Medicine at University of Tampere, Tampere, Finland. 7Heart Centre, Department of Cardiology, Tampere University Hospital, Tampere, Finland. 8Department of Thoracic, Cardiac and Vascular Surgery, Eberhard Karls University, Tübingen, Germany.
Address correspondence to: Axel Bauer, Medizinische Klinik III, Abteilung für Kardiologie und Herz-Kreislauferkrankungen, Eberhard-Karls-Universität Tübingen, Otfried-Müller-Str. 10, 72076 Tübingen, Germany. Phone: 49.7071.29.82922; Fax: 49.7071.29.4550; E-mail: bauer@thebiosignals.org.
Find articles by Nikus, K. in: PubMed | Google Scholar
1Medizinische Klinik III, Abteilung für Kardiologie und Herz-Kreislauferkrankungen, Eberhard Karls University, Tübingen, Germany. 2Division of Cardiology, Helsinki University Central Hospital, Helsinki, Finland. 31. Medizinische Klinik, Technische Universität München, Munich, Germany. 4Department of Clinical Physiology and 5Department of Biomedical Engineering, Tampere University of Technology, Tampere, Finland. 6Department of Clinical Chemistry, Fimlab Laboratories, School of Medicine at University of Tampere, Tampere, Finland. 7Heart Centre, Department of Cardiology, Tampere University Hospital, Tampere, Finland. 8Department of Thoracic, Cardiac and Vascular Surgery, Eberhard Karls University, Tübingen, Germany.
Address correspondence to: Axel Bauer, Medizinische Klinik III, Abteilung für Kardiologie und Herz-Kreislauferkrankungen, Eberhard-Karls-Universität Tübingen, Otfried-Müller-Str. 10, 72076 Tübingen, Germany. Phone: 49.7071.29.82922; Fax: 49.7071.29.4550; E-mail: bauer@thebiosignals.org.
Find articles by Eick, C. in: PubMed | Google Scholar
1Medizinische Klinik III, Abteilung für Kardiologie und Herz-Kreislauferkrankungen, Eberhard Karls University, Tübingen, Germany. 2Division of Cardiology, Helsinki University Central Hospital, Helsinki, Finland. 31. Medizinische Klinik, Technische Universität München, Munich, Germany. 4Department of Clinical Physiology and 5Department of Biomedical Engineering, Tampere University of Technology, Tampere, Finland. 6Department of Clinical Chemistry, Fimlab Laboratories, School of Medicine at University of Tampere, Tampere, Finland. 7Heart Centre, Department of Cardiology, Tampere University Hospital, Tampere, Finland. 8Department of Thoracic, Cardiac and Vascular Surgery, Eberhard Karls University, Tübingen, Germany.
Address correspondence to: Axel Bauer, Medizinische Klinik III, Abteilung für Kardiologie und Herz-Kreislauferkrankungen, Eberhard-Karls-Universität Tübingen, Otfried-Müller-Str. 10, 72076 Tübingen, Germany. Phone: 49.7071.29.82922; Fax: 49.7071.29.4550; E-mail: bauer@thebiosignals.org.
Find articles by Greiner, T. in: PubMed | Google Scholar
1Medizinische Klinik III, Abteilung für Kardiologie und Herz-Kreislauferkrankungen, Eberhard Karls University, Tübingen, Germany. 2Division of Cardiology, Helsinki University Central Hospital, Helsinki, Finland. 31. Medizinische Klinik, Technische Universität München, Munich, Germany. 4Department of Clinical Physiology and 5Department of Biomedical Engineering, Tampere University of Technology, Tampere, Finland. 6Department of Clinical Chemistry, Fimlab Laboratories, School of Medicine at University of Tampere, Tampere, Finland. 7Heart Centre, Department of Cardiology, Tampere University Hospital, Tampere, Finland. 8Department of Thoracic, Cardiac and Vascular Surgery, Eberhard Karls University, Tübingen, Germany.
Address correspondence to: Axel Bauer, Medizinische Klinik III, Abteilung für Kardiologie und Herz-Kreislauferkrankungen, Eberhard-Karls-Universität Tübingen, Otfried-Müller-Str. 10, 72076 Tübingen, Germany. Phone: 49.7071.29.82922; Fax: 49.7071.29.4550; E-mail: bauer@thebiosignals.org.
Find articles by Wendel, H. in: PubMed | Google Scholar
1Medizinische Klinik III, Abteilung für Kardiologie und Herz-Kreislauferkrankungen, Eberhard Karls University, Tübingen, Germany. 2Division of Cardiology, Helsinki University Central Hospital, Helsinki, Finland. 31. Medizinische Klinik, Technische Universität München, Munich, Germany. 4Department of Clinical Physiology and 5Department of Biomedical Engineering, Tampere University of Technology, Tampere, Finland. 6Department of Clinical Chemistry, Fimlab Laboratories, School of Medicine at University of Tampere, Tampere, Finland. 7Heart Centre, Department of Cardiology, Tampere University Hospital, Tampere, Finland. 8Department of Thoracic, Cardiac and Vascular Surgery, Eberhard Karls University, Tübingen, Germany.
Address correspondence to: Axel Bauer, Medizinische Klinik III, Abteilung für Kardiologie und Herz-Kreislauferkrankungen, Eberhard-Karls-Universität Tübingen, Otfried-Müller-Str. 10, 72076 Tübingen, Germany. Phone: 49.7071.29.82922; Fax: 49.7071.29.4550; E-mail: bauer@thebiosignals.org.
Find articles by Seizer, P. in: PubMed | Google Scholar
1Medizinische Klinik III, Abteilung für Kardiologie und Herz-Kreislauferkrankungen, Eberhard Karls University, Tübingen, Germany. 2Division of Cardiology, Helsinki University Central Hospital, Helsinki, Finland. 31. Medizinische Klinik, Technische Universität München, Munich, Germany. 4Department of Clinical Physiology and 5Department of Biomedical Engineering, Tampere University of Technology, Tampere, Finland. 6Department of Clinical Chemistry, Fimlab Laboratories, School of Medicine at University of Tampere, Tampere, Finland. 7Heart Centre, Department of Cardiology, Tampere University Hospital, Tampere, Finland. 8Department of Thoracic, Cardiac and Vascular Surgery, Eberhard Karls University, Tübingen, Germany.
Address correspondence to: Axel Bauer, Medizinische Klinik III, Abteilung für Kardiologie und Herz-Kreislauferkrankungen, Eberhard-Karls-Universität Tübingen, Otfried-Müller-Str. 10, 72076 Tübingen, Germany. Phone: 49.7071.29.82922; Fax: 49.7071.29.4550; E-mail: bauer@thebiosignals.org.
Find articles by Schreieck, J. in: PubMed | Google Scholar
1Medizinische Klinik III, Abteilung für Kardiologie und Herz-Kreislauferkrankungen, Eberhard Karls University, Tübingen, Germany. 2Division of Cardiology, Helsinki University Central Hospital, Helsinki, Finland. 31. Medizinische Klinik, Technische Universität München, Munich, Germany. 4Department of Clinical Physiology and 5Department of Biomedical Engineering, Tampere University of Technology, Tampere, Finland. 6Department of Clinical Chemistry, Fimlab Laboratories, School of Medicine at University of Tampere, Tampere, Finland. 7Heart Centre, Department of Cardiology, Tampere University Hospital, Tampere, Finland. 8Department of Thoracic, Cardiac and Vascular Surgery, Eberhard Karls University, Tübingen, Germany.
Address correspondence to: Axel Bauer, Medizinische Klinik III, Abteilung für Kardiologie und Herz-Kreislauferkrankungen, Eberhard-Karls-Universität Tübingen, Otfried-Müller-Str. 10, 72076 Tübingen, Germany. Phone: 49.7071.29.82922; Fax: 49.7071.29.4550; E-mail: bauer@thebiosignals.org.
Find articles by Gawaz, M. in: PubMed | Google Scholar
1Medizinische Klinik III, Abteilung für Kardiologie und Herz-Kreislauferkrankungen, Eberhard Karls University, Tübingen, Germany. 2Division of Cardiology, Helsinki University Central Hospital, Helsinki, Finland. 31. Medizinische Klinik, Technische Universität München, Munich, Germany. 4Department of Clinical Physiology and 5Department of Biomedical Engineering, Tampere University of Technology, Tampere, Finland. 6Department of Clinical Chemistry, Fimlab Laboratories, School of Medicine at University of Tampere, Tampere, Finland. 7Heart Centre, Department of Cardiology, Tampere University Hospital, Tampere, Finland. 8Department of Thoracic, Cardiac and Vascular Surgery, Eberhard Karls University, Tübingen, Germany.
Address correspondence to: Axel Bauer, Medizinische Klinik III, Abteilung für Kardiologie und Herz-Kreislauferkrankungen, Eberhard-Karls-Universität Tübingen, Otfried-Müller-Str. 10, 72076 Tübingen, Germany. Phone: 49.7071.29.82922; Fax: 49.7071.29.4550; E-mail: bauer@thebiosignals.org.
Find articles by Schmidt, G. in: PubMed | Google Scholar
1Medizinische Klinik III, Abteilung für Kardiologie und Herz-Kreislauferkrankungen, Eberhard Karls University, Tübingen, Germany. 2Division of Cardiology, Helsinki University Central Hospital, Helsinki, Finland. 31. Medizinische Klinik, Technische Universität München, Munich, Germany. 4Department of Clinical Physiology and 5Department of Biomedical Engineering, Tampere University of Technology, Tampere, Finland. 6Department of Clinical Chemistry, Fimlab Laboratories, School of Medicine at University of Tampere, Tampere, Finland. 7Heart Centre, Department of Cardiology, Tampere University Hospital, Tampere, Finland. 8Department of Thoracic, Cardiac and Vascular Surgery, Eberhard Karls University, Tübingen, Germany.
Address correspondence to: Axel Bauer, Medizinische Klinik III, Abteilung für Kardiologie und Herz-Kreislauferkrankungen, Eberhard-Karls-Universität Tübingen, Otfried-Müller-Str. 10, 72076 Tübingen, Germany. Phone: 49.7071.29.82922; Fax: 49.7071.29.4550; E-mail: bauer@thebiosignals.org.
Find articles by Bauer, A. in: PubMed | Google Scholar
Published March 18, 2014 - More info
J Clin Invest. 2014;124(4):1770–1780. https://doi.org/10.1172/JCI70085.
© 2014 The American Society for Clinical Investigation
Received: October 23, 2013; Accepted: January 16, 2014
-
Introduction
Sudden cardiac death (SCD) is the single most common cause of death in the industrialized world (1). A substantial proportion of SCD cases occur in patients after myocardial infarction (MI). Randomized trials have demonstrated that in high-risk patients after MI, mortality can be effectively reduced by prophylactic implantation of a cardioverter-defibrillator (ICD) (2). Consequently, identification of high-risk individuals is a major objective in cardiology. Current guidelines recommend the assessment of left ventricular ejection fraction (LVEF) as the gold standard risk predictor (3, 4); however, this approach lacks both sensitivity and specificity (1, 5). Therefore, development of novel risk markers is of great clinical interest.
Assessment of repolarization instability may more directly estimate the risk of fatal cardiac arrhythmias (6). It is well known from experimental and clinical studies that enhanced sympathetic activity is a key factor leading to the destabilization of myocardial repolarization (7–14). However, without directly recording neural activity, which is impractical in the clinical setting, assessment of the sympathetic effect on myocardial repolarization has not been possible to date. As sympathetic activity is organized in a series of low-frequency bursts (15–19), we postulated that repolarization changes induced by the sympathetic nervous system would exhibit low-frequency periodic features.
In the present study, we propose what we believe is a novel way to assess the sympathetic effect on cardiac repolarization. We developed a technology and uncovered periodic components of repolarization in the low-frequency spectral range (≤0.1 Hz), which we termed periodic repolarization dynamics (PRD). The first part of this article focuses on the physiological properties of PRD, including activation and blockade of the sympathetic nervous system. In the second part of this investigation, we assess the prognostic meaning of enhanced PRD in patients surviving acute MI (post-MI cohort; Figure 1A) and patients undergoing clinically indicated exercise testing (stress-test cohort; Figure 1B). In the stress-test cohort we also tested the prognostic meaning of exercise-induced T-wave alternans (TWA), which is presently considered to be the strongest existing marker of repolarization instability.
Figure 1CONSORT flow diagrams. Enrollment, follow-up, and analysis in the post-MI and stress-test cohorts.
-
Results
Repolarization is subject to low-frequency periodic modulations. We developed a technique to dynamically track repolarization dynamics and to quantify their periodic components. Details of the methodology are reported in Methods. Briefly, we used standard, high-resolution, surface ECG recorded in or converted to the orthogonal Frank lead configuration. As electrocardiographic repolarization is a phenomenon occurring in both space and time, we integrated the spatiotemporal information of each T-wave into a single vector, T°. We used the angle dT° between successive repolarization vectors as an estimate of the instantaneous repolarization instability (Figure 2, A–C). We observed characteristic low-frequency oscillations in dT° in health and disease (Figure 2D). In order to quantify these low-frequency (≤0.1 Hz) periodic patterns, we employed wavelet analysis (Figure 2E).
Figure 2Assessment of PRD. (A) Illustration of the weight-averaged vector of repolarization (T°) for each T-wave from surface ECG recorded in the Frank leads configuration. (B) Three-dimensional visualization of successive T° vectors projected into virtual spheres. The angle dT° between successive repolarization vectors was used as an estimate of instantaneous repolarization instability. (C and D) The dT° signal exhibits characteristic low-frequency oscillations. C shows dT° values for beats #219-223, corresponding to the spheres in B. (E) Quantification of PRD using wavelet analysis. PRD was defined as the average wavelet coefficient corresponding to frequencies of 0.1 Hz or less.
PRD is not an epiphenomenon of underlying heart rate variability. We tested whether PRD was present in the absence of heart rate variability (HRV). We studied 10 individuals (median age 52 [interquartile range (IQR) 32] years, 5 females), who underwent a clinically indicated electrophysiological (EP) study at our institution. Patient characteristics are provided in Methods. We compared 5-minute episodes of spontaneous sinus rhythm to 5-minute episodes during fixed atrial stimulation, which was set above the spontaneous heart rate. Fixed atrial pacing almost abolished HRV (P < 0.001; Supplemental Table 1; supplemental material available online with this article; doi: 10.1172/JCI70085DS1), but exerted only minimal, nonsignificant effects on PRD (ratio of PRD after provocation to PRD before provocation [PRD ratio] 0.75, 95% CI 0.50–1.17, P = 0.193; Figure 3A, Supplemental Figure 1A, and Supplemental Table 1).
Figure 3Physiological and pharmacological provocations. Effects of fixed atrial stimulation (i), tilt-table testing (ii), exercise (iii), and pharmacological beta blockade (iv) on PRD. PRD ratio was plotted on a logarithmic axis and used to quantify the effect of each procedure.
PRD is not an epiphenomenon of underlying respiratory activity. To test whether PRD was present in the absence of spontaneous breathing, we performed an experimental study in a swine model. Seven female domestic pigs were mechanically ventilated and sedated with α-chloralose, which has been shown to induce only minimal effects on the cardiac autonomic nervous system (20). Respiratory frequency and tidal volume were maintained constant by means of volume-controlled ventilation. Details of the experimental design are provided in Methods. PRD occurred independently of respiratory activity, as illustrated in Figure 4A. There was no interference between respiratory activity and PRD in any animal, as confirmed by spectral and crossspectral analysis (Figure 4, B and C; median coherence 0.044 [IQR 0.026]; P < 0.001 for the difference from the threshold of 0.5).
Figure 4Effect of respiration on PRD in a volume-controlled ventilated swine. (A) Signals of respiratory activity (green) and dT° (blue). Respiratory activity was recorded by a piezoelectric thoracic sensor. The dT° signal exhibits typical low-frequency oscillations occurring independently from respiratory activity. (B) Spectral analysis of respiratory activity and the dT° signal. Power spectra were normalized by their maximum value. (C) Cross-spectral analysis of respiratory activity and the dT° signal showing a lack of interference between both signals.
PRD is enhanced by sympathetic activation and suppressed by sympathetic blockade. We tested the effects of sympathetic activation on PRD in 11 healthy male volunteers (median age 24 [IQR 3] years). Sympathetic activation was achieved by means of head-up tilt testing and low-intensity exercise. Both tilt-table testing (PRD ratio 1.80, 95% CI 1.35–2.58, P = 0.005; Figure 3B, Supplemental Figure 1B, and Supplemental Table 1) and low-intensity exercise (PRD ratio 3.85, 95% CI 2.49–5.61, P = 0.001; Figure 3C, Supplemental Figure 1B, and Supplemental Table 1) led to substantial enhancement of PRD.
Conversely, we tested the effects of antiadrenergic intervention in 10 patients (median age 57 [IQR 21] years, 7 females) undergoing an EP study at our institution. Antiadrenergic intervention was achieved by pharmacological beta blockade. The diagnostic protocol is described in Methods. Beta blockade caused a striking suppression of PRD in all patients (PRD ratio 0.41, 95% CI 0.28–0.61, P = 0.002; Figure 3D, Supplemental Figure 1C, and Supplemental Table 1).
For comparison, the effects of sympathetic activation and blockade on the low-frequency component of heart-rate variability are shown in Supplemental Table 1.
Increased PRD predicts total and cardiovascular mortality after MI. We tested the prognostic significance of PRD in a cohort of 908 patients from the Autonomic Regulation Trial (median age 61 [IQR 17] years, 174 females) who survived an acute MI (Figure 1A and Table 1) (21, 22). Sixty-nine patients died within the first 5 years of follow-up. Representative resting dT° signals in a patient who survived the follow-up period and in a patient who suddenly died 8 months after index MI are depicted in Figure 5, A and B, respectively. Although low-frequency oscillations in dT° were evident in both patients, the amplitudes of PRD were much higher in the nonsurviving patient. The level of PRD was significantly associated with 5-year mortality (6.67 [IQR 8.58] deg2 vs. 2.66 [IQR 3.93] deg2; P < 0.001). For subsequent survival analyses, we dichotomized PRD at the upper quartile of the study population. The 227 patients with PRD greater than or equal to 5.75 deg2 (Figure 5C) had a 5-year risk of death of 18.2% compared with 4.1% in the 681 patients with PRD of less than 5.75 deg2 (P < 0.001). Both uni- and multivariable analyses for the prediction of 5-year total mortality indicated that PRD greater than or equal to 5.75 deg2 was the strongest single risk predictor in the study cohort (Table 2 and Supplemental Figure 2). The predictive value of PRD greater than or equal to 5.75 deg2 was independent of that of established risk markers, including reduced LVEF of 35% or less (3, 4), the Global Registry of Acute Coronary Events (GRACE) score (23), the presence of diabetes mellitus, elevated mean heart rate, reduced HRV, and increased QT variability index (QTVI) (24). Subsequently, we assessed the incremental prognostic value of PRD to established risk-prediction models (Supplemental Table 2). PRD significantly improved all tested risk-prediction models based on the combination of LVEF, GRACE score, respiratory rate, and HRV parameters. Subgroup analyses revealed that increased PRD was a particularly strong predictor of mortality in the 179 post-MI patients who also suffered from diabetes mellitus, identifying a group of 179 patients with a cumulative 5-year mortality rate of 38.8% (Figure 5D).
Figure 5PRD in post-MI patients. (A) Typical dT° signal (blue line) obtained from a 50-year-old post-MI patient who survived the 5-year follow-up period. The signal shows characteristic low-frequency oscillations. For better illustration of these oscillations, a low-pass filter was applied and plotted on top of the original signal (black line). (B) Typical dT° signal (red line) from a 75-year-old post-MI patient who suddenly died 8 months after MI. Compared with the survivor, the amplitude of PRD was substantially enhanced. (C) Cumulative mortality rates of patients stratified by PRD of 5.75 deg2 or more. (D) Cumulative mortality rates of patients stratified by PRD of 5.75 deg2 or more and presence of diabetes mellitus.
Table 2Univariable and multivariable association of risk markers with 5-year all-cause and cardiovascular mortality in 908 survivors of acute MI (post-MI cohort)
Finally, we also investigated whether PRD predicted cardiovascular mortality. Of the 69 deaths, 36 were cardiovascular deaths. As shown in Table 2, PRD greater than or equal to 5.75 deg2 was also a strong and independent predictor of 5-year cardiovascular mortality.
The predictive value of PRD is complementary to that of exercise-induced TWA. To test the predictive values of PRD and TWA, we studied 2,965 patients (median age 57 [IQR 16] years, 1,187 females) from the Finnish Cardiovascular Study (median age 57 [IQR 16], 1,187 females; Figure 1B and Table 1) who underwent a clinically indicated exercise test (25). During a median follow-up of 6 years, 309 patients died. In all patients, TWA was measured during exercise by the modified moving average (MMA) method (25–27). PRD was assessed in the preexercise period with patients sitting on a bicycle ergometer. As expected, PRD levels in this cohort were higher than those in the post-MI cohort, where PRD was estimated in the supine resting position (9.2 [IQR 13.37] deg2 vs. 2.82 [IQR 4.34] deg2, respectively; P < 0.001). Both PRD and TWA were significantly associated with mortality (8.96 [IQR 13.23] deg2 vs. 12.04 [IQR 16.32] deg2, P < 0.001, and 23.00 [IQR 15] μV vs. 26.00 [IQR 17] μV, P < 0.001, respectively). Univariable Cox regression analysis showed that both markers were strong predictors of total mortality (standardized coefficients 0.203, 95% CI 0.113–0.293, P < 0.001 for PRD; and 0.256, 95% CI 0.164–0.348, P < 0.001 for TWA). This remained true on multivariable analysis, which also included age, sex, previous MI, presence of diabetes mellitus, and treatment with beta-blockers (Table 3). The significant crossterm between TWA and PRD (TWA × PRD) indicated that the relationship between the outcome and one predictor was dependent on the levels of the other predictor. We therefore tested the additive prognostic value of PRD for different levels of TWA. As illustrated in Supplemental Figure 3, PRD provided incremental prognostic information at all levels of TWA.
Table 3Multivariable association of TWA and PRD with all-cause and cardiovascular mortality in 2,965 patients undergoing a clinically indicated exercise test (stress-test cohort)
Of the 309 deaths, 138 were cardiovascular deaths. Increased preexercise PRD was also a significant predictor of cardiovascular mortality in univariable (standardized coefficient 0.256, 95% CI 0.126–0.385; P < 0.001) and multivariable analysis (Table 3).
-
Methods
Participants. The physiological properties of PRD were studied in 3 cohorts at the University Hospital of Tübingen. We tested the effects of fixed atrial pacing (atrial-pacing cohort) in 10 individuals (median age 52 [IQR 42] years, 5 females) undergoing a clinically indicated diagnostic EP study. Indications for EP studies were paroxysmal supraventricular tachycardia in 7 patients and evaluation of unexplained syncope in 3 patients. We investigated the effect of beta blockade in 10 patients (median age 57 [IQR 21] years, 7 females) undergoing an EP study for paroxysmal supraventricular tachycardia (adrenergic-blockade cohort). In both EP studies, all patients were in sinus rhythm, had normal LVEF, were not suspected of suffering from coronary artery disease, and had no significant valve stenosis or insufficiency on echocardiography. We also studied the effects of passive head-up tilt and low-intensity exercise in 11 healthy male volunteers (median age 24 [IQR 3] years, adrenergic-activation cohort).
The prognostic power of PRD was tested in 908 survivors (median age 61 [IQR 17] years, 174 females) of acute MI (post-MI cohort; Figure 1A and Table 1) and 2,965 patients (median age 57 [IQR 16] years, 1,187 females) undergoing clinically indicated exercise testing (stress-test cohort; Figure 1B and Table 1). Patients in the post-MI cohort were enrolled between May 2000 and March 2005 at 2 university centers in Munich, Germany: the German Heart Centre and the Klinikum Rechts der Isar (21, 22). Eligible patients had survived acute MI (<4 weeks), were aged 80 years or more, had sinus rhythm, and did not meet the criteria for secondary prophylactic implantation of ICD before hospital discharge. Patients in the stress-test cohort were included between October 2001 and December 2008 at the Tampere University Hospital (Finnish Cardiovascular Study) (25). Eligible patients were aged 30–80 years, were in sinus rhythm, and underwent a clinically indicated exercise test.
Procedures. We performed EP studies according to the hospital’s standard operating procedures. No study-specific invasive procedures were performed on any patient. We did not sedate the patients. All EP studies required placement of a pacing electrode in the right atrium. Atrial pacing was performed at a fixed cycle length (CL), below sinus rhythm CL and slightly above Wenckebach CL. In the atrial-pacing cohort, we compared a 5-minute recording during undisturbed sinus rhythm to a 5-minute recording during fixed atrial stimulation. In the adrenergic-blockade cohort, we compared 5-minute tracings before and after i.v. administration of 0.1 mg/kg metoprolol. Fixed atrial pacing during the entire procedure was used to ensure constant heart rate.
Subjects in the adrenergic-activation cohort were not allowed to eat or drink coffee for 12 hours before the tests. Vigorous exercise and alcohol were forbidden for 48 hours before the tests. All healthy volunteers lay in a supine position in a quiet room for at least 15 minutes before data collection. We used 2 provocations: 2-minute passive head-up tilt-test at 45° and 5-minute low-intensity exercise using a bicycle ergometer. For the latter test, the individual workload was set to achieve a constant heart rate of 110 bpm. For all physiological studies, we used high-resolution (2,048 Hz) digital ECG (TMS; Porti System) recorded in Frank leads configuration throughout the entire procedure.
For the post-MI cohort, we used 30-minute high-resolution (1,600 Hz) digital ECG (TMS; Porti System) recorded in Frank leads configuration. Recordings were performed within the second week after MI in resting conditions in the morning hours and in a supine position. We additionally performed a 24-hour Holter recording (Oxford Excel Holter System, Oxford Instruments; Pathfinder700, Reynolds Medical; and Mortara Holter System, Mortara Instrument) within the second week after MI. For the stress-test cohort, an upright bicycle was used for the exercise test. The workload was increased from 20 to 30 W in a step-wise manner (10 to 30 W/min). For calculation of PRD, a preexercise period of at least 2.5 minutes was recorded using 12-channel digital ECG (500 Hz), which was converted into the Frank leads configuration by means of the inverse Dower matrix (39).
Assessment of PRD. The technique used to calculate PRD is illustrated in Figure 2 and in Supplemental Figures 4–6. The prerequisite for computing dT° is an ECG tracing recorded in or converted to the 3 orthogonal axes X, Y, and Z. The time positions of the T-waves were identified using previously published algorithms (40, 41). The end of each T-wave was set as the reference point (amplitude = 0 mV). The first step in calculating the new parameter was to transform the Cartesian coordinates X, Y, and Z (Supplemental Figure 4A) into a time series of polar coordinates defined by 2 angles (elevation and azimuth) and the resultant-force amplitude XYZ (Supplemental Figure 4B). For example, we selected a time point t1 (Supplemental Figure 4B) and decomposed the XYZ vector into 2 orthogonal vectors on the y axis and the transverse (XZ) plane. The angle between the vector and the y axis was termed the elevation (42) (Supplemental Figure 4D), with an angle of 0° defined as the vector pointing to the caudal direction. The angle between the vector on the transverse plane and the x axis was termed the azimuth (42).
On the basis of the 3 new time signals of the polar coordinates, we defined the weight-averaged direction of repolarization, which can be described by a set of 2 polar coordinates that we called the weight-averaged azimuth (WAA) and the weight-averaged elevation (WAE). WAA and WAE can be calculated using Equations 1 and 2, respectively. For each time point t, the resultant-force amplitude XYZ, represented as Amp(t) in Equations 1 and 2, was multiplied by the corresponding values for azimuth and elevation at the same time point. The (Amp(t) × Angle(t)) products were initially summed for the entire duration of the T-wave and thereafter divided by the sum of all resultant-force amplitudes. The result of each equation represents the “with-the-amplitude weighted” average angle, which is measured by means of the same units (deg rad) as the angle in Equations 1 and 2. Using the repolarization wave of Supplemental Figure 4 as a backbone, exemplary WAA and WAE values were calculated as illustrated in Supplemental Figure 5.
(Equation 1)
(Equation 2)We used the angle dT° between successive repolarization vectors as an estimate of the instantaneous degree of repolarization instability (Figure 2, A–C). The angle dT° was calculated using the dot product (scalar product) equation (43), which by 2 vectors of the same length r can be simplified to Equation 3 as illustrated in Supplemental Figure 6. The dT° signal was linearly interpolated with a sampling rate of 2 Hz and filtered using a low-pass filter to remove artifacts. In order to quantify the periodic components of dT°, we employed continuous wavelet transformation (Figure 2D). The continuous wavelet transformation provides wavelet coefficients for each scale at each time point. For each scale, the average wavelet coefficient was computed. Finally, scales were converted to pseudofrequencies using an established algorithm (44). PRD was defined as the average wavelet coefficient in the frequency range of 0.1 Hz or less (Figure 2E).
(Equation 3)Assessment of TWA. We assessed TWA by the time-domain MMA method according to previously established technologies (26) (GE Healthcare version 5.2). In brief, the MMA algorithm separates odd from even beats. The average morphologies of both the odd and even beats were calculated separately and continuously updated by a weighting factor of 1/8 or 1/32 of the difference between the ongoing average and the new incoming beats. The update was calculated for every incoming beat, resulting in continual moving averages of the odd and even beats. This approach makes the MMA suitable for TWA analysis during the period of activity or during periods of fluctuating heart rates (non–steady state periods) (45). In addition, algorithms were incorporated to reduce the influence of noise and artifacts, such as those caused by pedaling and respiration (46). The TWA values were calculated continuously during the entire exercise test, from rest to recovery, using all precordial leads. Finally, the maximum TWA value at heart rates of less than 125 bpm was derived.
Assessment of other risk predictors. We assessed LVEF by echocardiography or angiography. We obtained short-term and 24-hour HRV in time and frequency domains as previously proposed (47). Since the standard deviation of all normal-to-normal intervals (SDNN) provided the strongest prognostic power of all HRV measures, we used SDNN as a marker of HRV. We assessed QTVI from the resting ECGs according to previously published technological methods (24). We calculated the GRACE score, which combines several clinical risk factors, specifically patient age, history of previous MI and congestive heart failure, ST-segment deviation, elevated cardiac enzymes, renal impairment, systolic blood pressure and heart rate upon admission, and percutaneous coronary interventions during the hospital stay (23).
Animal study. Seven female domestic pigs (60–78 kg) were preanesthetized with propofol (2 mg/kg i.v.) and anesthetized with α-chloralose (150 mg/kg i.v. with supplemental doses of 600 mg in 60 ml saline as required), which has been shown to induce only minimal effects on the cardiac autonomic nervous system (20). Immediately after induction of anesthesia, the trachea was cannulated and the lungs were mechanically ventilated with room air. Constant respiratory frequency and tidal volume were maintained by means of volume-controlled ventilation with a fixed tidal volume (6 ml/kg) and a fixed respiratory rate. In each animal, the respiratory rate was set individually (respiratory rate 12–18 per minute corresponding to a frequency of 0.20–0.30 Hz) to maintain normal end-tidal CO2. Respiratory activity was recorded by a piezoelectric thoracic sensor (48). Two hours after the administration of Propofol, a high-resolution 30-minute ECG (2,048 Hz) was recorded in the Frank leads configuration.
Statistics. We present continuous variables as medians with IQRs. Categorical data are presented as proportions. Results are presented as mean values with 95% CI. Results of physiological and EP studies are presented as the ratio of the value after provocation to the corresponding value before provocation with 95% CI. Differences in the logarithmic ratios were assessed by means of a paired Wilcoxon signed-rank test. To evaluate the effects of respiratory activity on PRD, we estimated the square coherence function between respiratory and dT° signals using the cross-spectral method (49). The coherence function (range 0–1) expresses the linear coupling between 2 signals in the frequency domain (50). A square coherence function greater than 0.5 was considered significant (19, 51, 52). The end points of both prognostic studies were all-cause and cardiovascular mortality. We used the standardized definition of cardiovascular death (53, 54). The median follow-up time in the post-MI cohort was 5 years. PRD was dichotomized at the upper quartile of the study population. For dichotomization of other risk markers, we used established cutoff values of 35% or less for LVEF (55), –0.47 or more for QTVI (24), greater than 75 for mean heart rate (56), 70 ms or less for SDNN (56), and 120 or more for the GRACE score (23). We estimated survival curves using the Kaplan-Meier method. Multivariable analyses were implemented by the adaptation of Cox and multinomial logistic regression models. The latter method was used to calculate integrated discrimination improvement (IDI) scores (57). The median follow-up time in the stress-test cohort was 6 years. The prognostic powers of PRD and TWA were tested with univariable and multivariable Cox regression analysis,including age, sex, previous MI, the presence of diabetes mellitus, treatment with beta blockers, and the crossterm between TWA and PRD (TWA × PRD). PRD, TWA, and age were normalized by subtraction of their mean value and division by their SD and were included as scalar factors in the multivariable model. Differences were considered statistically significant when the 2-sided P value was less than 0.05. All statistical analyses were performed using CRAN R, version 2.15.1.
Study approval. The ethics committees of Tübingen, Tampere, and Munich approved the studies performed in the physiological, stress-test, and post-MI cohorts, respectively. Written informed consent was obtained from each participant. The animal protocol was in accordance with the German guidelines for use of living animals and was approved by the local governmental commission for animal research (K 5/10, Regierungspraesidium Tübingen, Baden-Wuerttemberg, Germany).
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)